Shop

Author at Microdose

Microdose

At our core, we champion integrity, diversity, and objectivity, providing trusted content that unites a wide array of experts and fosters unbiased opinions, ultimately empowering the psychedelic medicine community to flourish and make a positive impact on the world.

Health & Wellness

5 May 2023

Mental Health Awareness: Depression

May is Mental Health Awareness Month. And with the psychedelic medicine space being, at its core, about improving people’s lives and mental well-being, Microdose is doing its part to support...

By Microdose

Science

5 May 2023

What Is MDMA? An Introduction

Microdose is devoting the month of May to an exploration of MDMA (MDMay, get it?). Today, we start with an introductory look at What Is MDMA? Stay tuned for more...

By Microdose

Science

28 Apr 2023

LSD for Depression: A Closer Look

As the search for effective treatments for depression continues, researchers have begun to revisit LSD as a treatment for depression....

By Microdose

Health & Wellness

27 Apr 2023

Microdosing LSD: Exploring Sub-Perceptual Doses

In recent years, the practice of microdosing LSD (and other psychedelics) has garnered significant attention and curiosity....

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Science

21 Apr 2023

What is LSD? Research in the Modern Era

To celebrate Bicycle Day, Microdose is devoting the month of April to an exploration of LSD....

By Microdose

Industry

20 Apr 2023

Intiem Secures Intellectual Property Rights for AI-Driven VR Platform Featuring AI Virtual Sexual Wellness Therapists

Intiem, a leading technology company focused on sexual wellness, is pleased to announce that it has secured the intellectual property rights for an AI-driven VR platform featuring AI Virtual Sexual...

By Microdose

Science

20 Apr 2023

What is LSD? A Look at LSD Research (1950-1980)

To help celebrate Bicycle Day, Microdose is devoting the month of April to an exploration of LSD....

By Microdose

Culture

19 Apr 2023

Bicycle Day & Albert Hofmann: Celebrating LSD and Modern Day Psychedelics

Today is Bicycle Day, one of psychedelics’ unofficial birthdays....

By Microdose

Industry

13 Apr 2023

Psychedelics and the Evolution of Mental Health Care

In a post-pandemic era, it goes without saying that we’ve seen a massive shift in the way that we perceive mental health....

By Microdose

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.